Periprocedural Stroke Research Articles

Virtual reality-assisted distraction during transcatheter aortic valve implantation under local anaesthesia: A randomised study

BackgroundA minimal approach, using local anaesthesia alone, has been advocated to promote faster transcatheter aortic valve replacement (TAVR) procedures in intermediate-risk patients. Pre- and periprocedural anxiety and pain remain a concern. Virtual reality (VR) is a form of non-pharmacological distraction that can potentially modulate pain and anxiety. This randomised study explored whether VR reduces pain and anxiety during TAVR without sedation and compared the effects of VR with those of standard care. Methods and resultsBetween June 2022 and March 2023, 207 patients underwent transfemoral TAVR (TF-TAVR). Of these, 117 (56.5%) patients were willing to participate in the study and met the educational background and mental status criteria for assessment. Fifty-nine patients underwent TF-TAVR with VR glasses (VR group). Fifty-eight patients underwent standard TF-TAVR without VR (control group; CG). Post-interventional anxiety scores (STAI-S) (31.5 ± 13.4 vs. 38.5 ± 19.2, p = 0.02) and the perceived duration of the procedure (60.1 ± 32.3 vs. 73.0 ± 32.4, p = 0.04) were lower in the VR than in the CG. Procedure time, pain, and anxiety scores (visual analogue scale) were similar between the groups. The complication rate was low and not associated with VR. Post-interventional delirium occurred in nine patients, and was similar between the groups (VR: 4 [6.8%] vs. CG: 5 [8.6%], p = 0.71). No periprocedural strokes were observed. ConclusionVR for TAVR is feasible and safe and expands the non-drug spectrum of therapy for anxiety and pain in patients undergoing TAVR with a minimalistic approach.

Using Artificial Intelligence in Predicting Ischemic Stroke Events After Percutaneous Coronary Intervention.

Ischemic stroke (IS) is an uncommon but severe complication in patients undergoing percutaneous coronary intervention (PCI). Despite significant morbidity and economic cost associated with post PCI IS, a validated risk prediction model is not currently available. We aim to develop a machine learning model that predicts IS after PCI. We analyzed data from Mayo Clinic CathPCI registry from 2003 to 2018. Baseline clinical and demographic data, electrocardiography (ECG), intra/post-procedural data, and echocardiographic variables were abstracted. A random forest (RF) machine learning model and a logistic regression (LR) model were developed. The receiver operator characteristic (ROC) analysis was used to assess model performance in predicting IS at 6-month, 1-, 2-, and 5-years post-PCI. A total of 17,356 patients were included in the final analysis. The mean age of this cohort was 66.9 ± 12.5 years, and 70.7% were male. Post-PCI IS was noted in 109 patients (.6%) at 6 months, 132 patients (.8%) at 1 year, 175 patients (1%) at 2 years, and 264 patients (1.5%) at 5 years. The area under the curve of the RF model was superior to the LR model in predicting ischemic stroke at 6 months, 1-, 2-, and 5-years. Periprocedural stroke was the strongest predictor of IS post discharge. The RF model accurately predicts short- and long-term risk of IS and outperforms logistic regression analysis in patients undergoing PCI. Patients with periprocedural stroke may benefit from aggressive management to reduce the future risk of IS.

Safety of Cardiac Computed Tomography to Exclude Left Atrial Appendage Thrombus Prior to Direct Current Cardioversion in Patients With Atrial Arrhythmias

Cardiac computed tomography (CCT) is a feasible imaging modality to exclude left atrial appendage (LAA) thrombus prior to pulmonary vein isolation procedures but has not been routinely used prior to direct current cardioversion (DCCV) for atrial arrhythmias until piloted during the COVID-19 pandemic. The safety of CCT to exclude LAA thrombus is evaluated in this study. All patients with atrial arrhythmias requiring DCCV as inpatients at Middlemore Hospital between 1 September 2020 to 31 December 2022, and who underwent CCT to exclude LAA thrombus were prospectively collected using the All New Zealand Acute Coronary Syndrome-Quality Improvement (ANZACS-QI) linked cardiac CT registry database. Patients’ clinical records were reviewed for the combined primary outcome of periprocedural and 60-day death, and thromboembolic events including cerebrovascular accidents. A total of 217 patients (64.5% male, mean age 57.8±14 years) underwent CCT during the study period. The majority (37%) were European, 19.8% were Māori, 30.4% were Pasifika, and 7% were other ethnicity. The mean body mass index was 34.8±8 kg/m2. Severe left ventricular systolic dysfunction was present in 70 (32.2%) patients. No LAA thrombus or slow flow was seen in 192 (88.4%) CCT scans. Transoesophageal echocardiography (TOE) was performed in 17 patients with LAA thrombus or slow flow on CCT, of which six had LAA thrombus. Direct current cardioversion was performed in 180 patients with no periprocedural or 60-day stroke. No deaths were recorded. Cardiac CT appears to be a safe alternative to TOE for excluding LAA thrombus prior to DCCV.

Transcarotid artery revascularization for the management of blunt cerebrovascular injuries-is it a game changer?

In their 10 patient case series, Walker et al, describe excellent outcomes from the use of transcarotid artery revascularization (TCAR) for the treatment of patients with severe blunt cerebrovascular injuries (BCVI).1Dr. Patrick Walker et al. Transcarotid Artery Revascularization in Blunt Carotid Injury. J Vasc Surg Cases Innov Tech. 20XX, 1(1), XX-XX. doi: XXXX.Google Scholar. For a single center over only 2 years this is a large cohort for a relatively rare problem. It is important to note that the primary treatment for BCVI is antithrombotic therapy with antiplatelets and/or anticoagulation. It has been shown that transfemoral carotid artery stenting for BCVI is rarely necessary or beneficial over antithrombotic therapy and the EAST guidelines recommend against routine stenting of grade II or III BCVI.(2)Burlew C.C. Biffl W.L. Moore E.E. Pieracci F.M. Beauchamp K.M. Stovall R. Wagenaar A.E. Jurkovich G.J. Endovascular stenting is rarely necessary for the management of blunt cerebrovascular injuries.J Am Coll Surg. 2014; 218: 1012-1017https://doi.org/10.1016/j.jamcollsurg.2014.01.042Crossref PubMed Scopus (45) Google Scholar,(3)Kim D.Y. Biffl W. Bokhari F. Brakenridge S. Chao E. Claridge J.A. Fraser D. Jawa R. Kasotakis G. Kerwin A. et al.Evaluation and management of blunt cerebrovascular injury: A practice management guideline from the Eastern Association for the Surgery of Trauma.J Trauma Acute Care Surg. 2020; 88: 875-887https://doi.org/10.1097/TA.0000000000002668Crossref PubMed Scopus (32) Google Scholar The Denver group found an alarmingly high 45% occlusion rate in patients treated with stenting vs. only 5% in those treated with antithrombotic therapy and concluded that stenting for BCVI had an unacceptable risk profile.(4)Cothren C.C. Moore E.E. Ray C.E. Ciesla D.J. Johnson J.L. Moore J.B. Burch J.M. Carotid artery stents for blunt cerebrovascular injury: risks exceed benefits.Arch Surg. 2005; 140 (; discussion 485-486): 480-485https://doi.org/10.1001/archsurg.140.5.480Crossref PubMed Scopus (111) Google Scholar It seems clear that stenting is rarely indicated for BCVI and this is consistent with the experience of the Maryland Shock Trauma study, as the authors point out that their center diagnoses approximately 300 carotid BCVIs per year, of which only 2-3% were selected for TCAR. It's possible that TCAR may be associated with a lower stroke and complication rate in BCVI patients in a similar manner to its benefits for carotid occlusive disease. Namely, by the use of dynamic flow reversal, which was found by Naazie, et al. in their Vascular Quality Initiative study to be the primary mechanism for stroke protection in TCAR.(5)Naazie I.N. Magee G.A. Mathlouthi A. Elsayed N. Dakour-Aridi H. Malas M.B. Primary mechanism of stroke reduction in transcarotid artery revascularization is dynamic flow reversal.J Vasc Surg. 2021; 74: 187-194https://doi.org/10.1016/j.jvs.2020.10.082Abstract Full Text Full Text PDF PubMed Scopus (8) Google Scholar Although the focus of this series is on the novel use of TCAR in the setting of BCVI requiring stenting, the authors describe another innovation, which is the use of Supera stents (Abbott, Plymouth, MN). The authors state that they prefer Supera stents for this application because of its flexibility and length, as they often stent up to the skull base to treat the entirety of the injury. At first glance, this seems to be an usual choice, but their results suggest that the authors may be on to something. Further study is necessary to determine if TCAR is a gamechanger for the management of BCVI and which of these two innovations is the primary reason for improved outcomes. Transcarotid Artery Revascularization in Blunt Carotid InjuryJournal of Vascular Surgery Cases, Innovations and TechniquesPreviewTranscarotid artery revascularization (TCAR) with flow reversal has substantially changed the management of carotid artery stenosis, enabling an endovascular approach with a periprocedural stroke rate as low or lower than that of open carotid surgery. The use of TCAR in blunt carotid injury has not yet been described. Full-Text PDF Open Access

Transcarotid artery revascularization in blunt carotid injury.

Transcarotid artery revascularization (TCAR) with flow reversal has substantially changed the management of carotid artery stenosis, enabling an endovascular approach with a periprocedural stroke rate as low as or lower than that of open carotid surgery. The use of TCAR for blunt carotid artery injury has not yet been described. A review of the use of TCAR for blunt carotid artery injury was performed at a single center from October 2020 to August 2021. The patient demographics, mechanism of injury, and outcomes were collected and compared. Ten carotid stents were placed via TCAR in eight patients for hemodynamically significant blunt carotid artery injuries. No periprocedural neurologic events occurred, and all stents remained patent during short-term follow-up. TCAR is feasible and safe in the management of significant blunt carotid artery injuries. More data are needed regarding the long-term outcomes and ideal surveillance intervals.

Young patients undergoing carotid stenting procedures have an increased rate of procedural failure at 1-year follow-up

ObjectiveThe outcomes of patients with premature cerebrovascular disease (age ≤55 years) who undergo carotid artery stenting are not well-defined. Our study objective was to analyze the outcomes of younger patients undergoing carotid stenting. MethodsThe Society for Vascular Surgery Vascular Quality Initiative was queried for transfemoral carotid artery stenting (TF-CAS) and transcarotid artery revascularization (TCAR) procedures between 2016 and 2020. Patients were stratified based on age ≤55 or >55 years. Primary endpoints were periprocedural stroke, death, myocardial infarction (MI), and composite outcomes. Secondary endpoints included procedural failure (defined as ipsilateral restenosis ≥80% or occlusion) and reintervention rates. ResultsOf the 35,802 patients who underwent either TF-CAS or TCAR, 2912 (6.1%) were ≤55 years. Younger patients were less likely than older patients to have coronary disease (30.5% vs 50.2%; P < .001), diabetes (31.5% vs 37.9%; P < .001), and hypertension (71.8% vs 89.8%; P < .001), but were more likely to be female (45% vs 35.4%; P < .001) and active smokers (50.9% vs 24.0%; P < .001) Younger patients were also more likely to have had a prior transient ischemic attack or stroke than older patients (70.7% vs 56.9%; P < .001). TF-CAS was more frequently performed in younger patients (79.7% vs 55.4%; P < .001). In the periprocedural period, younger patients were less likely to have a MI than older patients (0.3% vs 0.7%; P < .001), but there was no significant difference in the rates of periprocedural stroke (1.5% vs 2.0%; P = .173) and composite outcomes of stroke/death (2.6% vs 2.7%; P = .686) and stroke/death/MI (2.9% vs 3.2%; P = .353) between our two cohorts. The mean follow-up was 12 months regardless of age. During follow-up, younger patients were significantly more likely to experience significant (≥80%) restenosis or occlusion (4.7% vs 2.3%; P = .001) and to undergo reintervention (3.3% vs 1.7%; P < .001). However, there was no statistical difference in the frequency of late strokes between younger and older patients (3.8% vs 3.2%; P = .129). ConclusionsPatients with premature cerebrovascular disease undergoing carotid artery stenting are more likely to be African American, female, and active smokers than their older counterparts. Young patients are also more likely to present symptomatically. Although periprocedural outcomes are similar, younger patients have higher rates of procedural failure (significant restenosis or occlusion) and reintervention at 1-year follow-up. However, the clinical implication of late procedural failure is unknown, given that we found no significant difference in the rate of stroke at follow-up. Until further longitudinal studies are completed, clinicians should carefully consider the indications for carotid stenting in patients with premature cerebrovascular disease, and those who do undergo stenting may require close follow-up.

Edge-to-Edge Transcatheter Mitral Valve Repair Using PASCAL vs. MitraClip: A Systematic Review and Meta-Analysis.

Transcatheter edge-to-edge repair (TEER) of the mitral valve (MV) can be performed using the PASCAL or MitraClip devices. Few studies offer a head-to-head outcome comparison of these two devices. PubMed, EMBASE, Cochrane Library, Clinicaltrials.gov and WHO's International Clinical Trials Registry Platform, from 1 January 2000 until 1 March 2023, were searched. Study protocol details were registered in the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD42023405400). Randomized Controlled Trials and observational studies reporting head-to-head clinical comparison of PASCAL and MitraClip devices were eligible for selection. Patients with severe functional or degenerative mitral regurgitation (MR) who had undergone TEER of the MV with either PASCAL or MitraClip devices were included in the meta-analysis. Data from six studies (five observational and one randomized clinical trial) were extracted and analyzed. The main outcomes were a reduction in MR to 2+ or less, improvement of New York Heart Association (NYHA) and 30-day all-cause mortality. Peri-procedural mortality, success rate and adverse events were also compared. Data from 785 and 796 patients that underwent TEER using PASCAL and MitraClip, respectively, were analyzed. Thirty-day all-cause mortality (Risk ratio [RR] = 1.51, 95% CI 0.79-2.89), MR reduction to maximum 2+ (RR = 1.00, 95% CI 0.98-1.02) and NYHA improvement (RR = 0.98, 95% CI 0.84-1.15) were similar in both device groups. Both devices had high and similar success rates (96.9% and 96.7% for the PASCAL and MitraClip group, respectively, p value = 0.91). MR reduction to 1+ or less at discharge was similar in both device groups (RR = 1.06, 95% CI 0.95-1.19). Composite peri-procedural and in-hospital mortality was 0.64% and 1.66% in the PASCAL and MitraClip groups, respectively (p value = 0.094). Rates of peri-procedural cerebrovascular accidents were 0.26% in PASCAL and 1.01% in MitraClip (p value = 0.108). Both PASCAL and MitraClip devices have high success and low complication rates for TEER of the MV. PASCAL was not inferior to MitraClip in reducing the MR level at discharge.

Sex-Related Outcomes in Asymptomatic Patients Undergoing Carotid Artery Stenting.

Aim of the study was to evaluate the influence of sex in asymptomatic patients undergoing carotid artery stenting (CAS). A retrospective observational study was conducted from January 2006 to December 2020. A total of 438 consecutive patients with asymptomatic carotid artery stenosis >70% underwent transfemoral CAS and were stratified in males (M) and females (F). Periprocedural 30-day outcomes were: stroke, death, and myocardial infarction (MI). Follow-up outcomes were: death and stroke rates (primary) and freedom from restenosis (FFR) and reintervention rates (secondary). Follow-up data were analyzed at 1, 5, and 10 years. Data were analyzed with χ2 test and Fisher's exact test and follow-up outcomes with Kaplan-Meier curves. The log-rank test was used to determine differences between the groups and univariate analysis to identify the association between risk factors and intraoperative details with mortality and restenosis rates. A total of 462 procedures were performed (M: n=321, 69.4%), in which 24 CAS were bilateral (5.5%). Mean age was 71.9±7.6 years (M: 72.1±7.8; F: 71.7±7.3). Periprocedural outcomes were: stroke rate 2.2% (n=10; M: n=5, 1.6%; F: n=5, 3.5%; p=0.176), mortality rate 0.6% (M: n=3, p=0.334), and stroke/death rate 2.8% (n=13; M: n=8, 2.5%; F: n=5, 3.5%; p=0.528); no cardiac events (MI) were recorded. A not-disabling (minor) stroke was detected in 3 males (0.9%), while a disabling (major) stroke was reported in 7 patients (1.7%) of whom 5 were ischemic events (M: n=2, 0.6%; F: n=3, 2.2%) and 2 were cerebral hemorrhages (F: 1.3%, p=0.046). Mean follow-up was 73.66±40.83 months (M: 72.66; F: 76.01; p=0.246). Overall survival rate was 96.1% (95% confidence interval [CI]: 93-98), 81.8% (95% CI: 77-86), and 45.5% (95% CI: 38-53) at 1, 5, and 10 years, respectively (p=0.236). The overall stroke rate was 0.3% (freedom from stroke [FFS]: 99.7%; 95% CI: 98-100), 0.9% (FFS: 99%; 95% CI: 98-100), and 4.3% (FFS: 95.7%; 95% CI: 89-98; M: n=6; F: n=2; p=0.774). Stroke-related mortality rate was 0.7% (FFS: 99.3%; 95% CI: 97-100) and 2.9% (FFS: 97.1%; 95% CI: 91-99) at 5 and 10 years, respectively, without differences between the groups (M: n=4; F: n=2; p=0.763). Overall FFR rate was 97.4% (95% CI: 95-99), 93.4% (95% CI: 90-96), and 89.5% (95% CI: 84-93; p=0.322). Two severe symptomatic restenosis (>70%, M) required a new endovascular revascularization. The sex variable does not influence outcomes of CAS in asymptomatic patients at short- and long-term follow-up, although females show a worst incidence of periprocedural major strokes. Carotid artery stenting may be safely proposed when a careful patient selection is applied. The sex variable has been advocated as a considerable factor that could influence the outcomes of transfemoral carotid artery stenting (CAS). Literature data are contrasting, even if different papers mainly reported that CAS is associated to worst outcomes in female patients. Our study shows that the sex-variable does not influence outcomes of CAS in asymptomatic patients at short and long-term follow-up, although females had a worst incidence of periprocedural major strokes. CAS may be safely proposed when a careful patient selection is applied.

Percutaneous transluminal angioplasty and stenting vs aggressive medical management on stroke or intracranial atherosclerotic stenosis: a systematic review and meta-analysis

There are currently two main treatment strategies mainly for high-risk patients: percutaneous transluminal angioplasty and stenting (PTAS) and aggressive medical management (AMM). However, the choice between PTAS or AMM remains controversial for patients with stroke or intracranial atherosclerotic stenosis (ICAS). The investigators searched the PubMed, Web of Science, Embase, Scopus, and Cochrane library databases. Randomized controlled trial (RCT) comparing PTAS and AMM for patients with stroke or ICAS were selected. RevMan 5.3 was used to analyze the results and assess risk of bias. The primary endpoints are stroke and death within 30 days after enrollment, or ischemic stroke in the territory of the qualifying artery beyond 30 days, and entire follow-up endpoints. The secondary outcomes were the disabling or fatal stroke, and incidence of death within 3 years. Four studies, 989 patients were included in this article. The AMM group was superior in the entire follow-up endpoint (OR 0.56; 95% CI 0.40, 0.79). The AMM also better in primary endpoint within 30 days (OR 0.32; 95% CI 0.17, 0.61). There was no significant difference beyond 30 days (OR 1.08; 95% CI 0.63, 1.86). The remaining outcomes, such as stroke and death, were not significantly different (P > 0.05). This meta-analysis shows AMM is significantly more effective than PTAS in subjects with ICAS due to the high rate of periprocedural stroke (OR 0.32; 95% CI 0.17, 0.61) and stroke during the entire follow-up (OR 0.56; 95% CI 0.40, 0.79) associated with PTAS. Furthermore, PTAS offers no additional benefits over AMM beyond 30 days (OR 1.08; 95% CI 0.63, 1.86).

Effect of the Pre-Operative Systemic Inflammatory Response on Outcomes Following Carotid Endarterectomy for Symptomatic Carotid Stenosis

Objective: Stroke accounts for over 100 000 acute hospital presentations per year in the UK, and approximately 4 500 carotid endarterectomies are performed annually in the UK.1 This is despite a relative paucity of cases performed for asymptomatic carotid stenosis, in comparison with other countries.1 Periprocedural stroke and death rates have fallen in recent years,2 although these remain notable risks necessitating careful patient selection and counselling. Chronic activation of the systemic inflammatory response (SIR) is prevalent in patients with atherosclerotic disease and influences both the pathogenesis and prognosis.3,4 The neutrophil:lymphocyte and platelet:lymphocyte ratios (NLR, PLR) are markers of the SIR, and are reported to provide prognostic value in patients with acute stroke,5 and in patients undergoing carotid endarterectomy.6 The Modified Glasgow Prognostic Score (mGPS) is calculated from C-reactive protein (CRP) and albumin and was originally described in patients with cancer.7 More recently mGPS has been shown to provide prognostic value in non-cancer patient groups.8 mGPS is representative of an alternative pathway activating the SIR and is not reported in relation to carotid endarterectomy outcomes. The present study describes experience of the prognostic value of these pre-operative markers of SIR in patients undergoing carotid endarterectomy.

AB-452642-2 COMPLICATIONS ASSOCIATED WITH CATHETER ABLATION OF ATRIAL FIBRILLATION IN CURRENT PRACTICE: INSIGHTS FROM A LARGE, REAL-WORLD COLLABORATION

Catheter ablation is a cornerstone treatment for symptomatic atrial fibrillation (AF) with major improvements in safety over time. However, rates of adverse events with use of current techniques in a contemporary quality-focused network remain undefined. Across a large, real-world sample, we sought to describe (1) rates of major, adverse events associated with catheter ablation of AF and (2) patient-level factors associated with complications. Utilizing the REAL-AF collaboration, a registry of contemporary AF ablation procedures with granular patient, procedural and follow-up data comprised of cases from over 50 operators across academic and non-academic sites, we evaluated all patients undergoing their first ablation procedure from January 2018 – June 2022. Risk-adjusted analyses were conducted to evaluate the relationship between patient factors and complications. Among 3144 patients (age 66.1 +/- 11.0 years, 42% female, 67.1% paroxysmal, 32.9% persistent) who underwent AF ablation, procedure-related complications (n =77) were identified in 65 patients (2.1%) with multiple complications occurring in 9 patients (0.2%). Most complications (n=70, 93.5%) occurred in the peri-procedural (within 30 days) period and 6.5% (n=5) after 30 days, the latter of which all represented vascular injuries (Figure). Major complications (18 of 72 peri-procedural complications, 25.0%) are defined, detailed, and associated data reported in the Figure. Unadjusted (16.0% without CHF vs. 33.3% with CHF, p = 0.045) and risk-adjusted (OR 2.8, 95% CI 1.03-7.60, p=0.045) analyses indicated history of CHF was associated with a composite outcome of major complications. Analyses of independent complications showed those who suffered from peri-procedural stroke (n=3) were of significantly greater age (77.3 +/- 5.5 years vs. 66.1 +/- 10.9 years, p=0.035). Risk-adjusted analyses showed history of vascular disease (OR 2.9, 95% CI 1.02-8.20, p=0.045) was associated with vascular injury (n=18). From 0-695 days post-procedure, 31 deaths occurred (unknown cause: 17, COVID-19 related: 4, heart failure: 2, cardiac arrest: 2). Major complications represent rare events among those undergoing AF ablation in current practice. Risk-adjusted analyses suggest a history of CHF is associated with major complications. Similarly, older age and a history of vascular disease are associated with stroke and vascular complications, respectively.

PO-03-175 COST-EFFECTIVENESS OF TRANSESOPHAGEAL ECHOCARDIOGRAM PRIOR TO ATRIAL FIBRILLATION ABLATION.

With universal adoption of uninterrupted anticoagulation (AC) it is suggested that transesophageal echo (TEE) screening for LA (left atrial) thrombus prior to AF ablation procedure could be omitted. Observational studies suggest that post-procedure stroke might not be completely prevented by TEE. Accumulating data on safety of AF ablation on uninterrupted AC together with a risk of TEE complications raise the question of indications for TEE in all AF ablation patients. We estimated the cost-effectiveness of TEE before AF ablation. Cost-effectiveness ratio was defined as the net costs of TEE including the cost of TEE complications and reduction of lifetime stroke costs divided by net health benefit gain. Health effect was quality-adjusted life-years (QALYs) due to post-ablation stroke or TEE complications. Costs and QALYs were discounted at 3%. Lifetime cost of stroke was assessed according to the modified Rankin Scale (mRS) at 1 year follow up. One way sensitivity analyses were performed for the incidence of TEE complications, stroke rate and severity. We assumed double the rate and half the rate of TEE complications. For stroke severity sensitivity analysis we redistributed severity towards non-mild strokes having more weight. For the stroke rate we added the LA thrombus detection rate by TEE (2%) to the literature reported incidence of post ablation stroke. Given the rarity of stroke after AF ablation, and the uncertainty of TEE effectiveness in preventing it, we reviewed cost-effectiveness analysis based on hypothetical stroke reduction by TEE of 25%, 50%, 75% and 100%. When TEE does prevents no strokes, TEE is dominated, adding $434,802,162 in costs and reducing health by 768 QALYs in 240,000 procedures per year. When TEE prevents all peri-procedural strokes, the cost-effectiveness ratio is $45,620 per QALY gained. TEE remains a dominated strategy in sensitivity analyses if it doesn’t prevent any strokes. When strokes are reduced by 50%, the cost effectiveness ratio exceeds $100,000 Our study found that when TEE prior to AF ablation on uninterrupted AC doesn’t prevent any strokes, TEE is dominated. Cost-effectiveness of TEE screening is sensitive to the level of stroke prevention it accomplishes. For TEE to be cost effective it must reduce the risk of stroke at least by 50%. RCTs are needed on effectiveness of TEE at preventing strokes in patients on uninterrupted AC to fully resolve the utility of TEE.

Periprocedural Cerebral Air Embolism; A Rare and Potentially Fatal Complication of Watchman Device (P3-5.028)

<h3>Objective:</h3> To study peri-procedural complications of Watchman device placement. <h3>Background:</h3> Left atrial appendage therapy with a Watchman device is a non-inferior ischemic stroke prevention strategy for patients with paroxysmal atrial fibrillation (pAF) deemed to be unsuitable for conventional anticoagulation. Peri-procedural air embolism is a known complication and can present with systemic emboli provoking ischemic strokes, coronary ischemia, or cardiac arrest. The PROTECT AF trial specifically documented 5 peri-procedural strokes out of 542 total procedures due to air embolism. We present two cases of periprocedural cerebral emboli resulting in potentially fatal complications. <h3>Design/Methods:</h3> Retrospective review of electronic medical records. <h3>Results:</h3> 81year old gentleman was noted to have acute change of decreased generalized responsiveness, and concomitant electrocardiographic change during Watchman deployment. Rapid reversal of anesthetic agents did not result in clinical improvement. Neurological exam showed asymmetric pupils, L&gt;R, and initially withdrew on all four extremities with rapid progression to flexor posturing to noxious stimulus. CT stroke protocol demonstrated an area of acute infarction in the right middle cerebral artery territory, associated with air in sulci. He required transfer to another facility for hyperbaric oxygen treatment. Follow up CT scan of head demonstrated complete resolution of air emboli, however his neurologic exam remained poor, and patient expired during hospital admission. <h3>Case 2:</h3> 61year old gentleman presented with periprocedural acute onset of right gaze deviation, left facial droop, left sided paralysis, sustained clonus, and left sensory deficit. CT stroke protocol showed hypodensity in the right MCA territory with air in sulci. He was transferred for hyperbaric oxygen therapy. After protracted rehabilitation, he lives independently with residual left sided weakness. <h3>Conclusions:</h3> Air embolism remains an under-recognized potentially fatal complication of Watchman device placement. These cases indicate the need to recognize air emboli as an etiology of periprocedural stroke requiring a unique treatment strategy including a framework for expedited hyperbaric access. <b>Disclosure:</b> Dr. Peshwe has nothing to disclose. Dr. Munir has nothing to disclose. Dr. Hatfield has nothing to disclose. The institution of an immediate family member of Dr. Adcock has received research support from NIH.

Causes of Early Mortality After Catheter Ablation of Atrial Fibrillation.

Recognition of the causes of early mortality after atrial fibrillation (AF) catheter ablation is essential for the improvement of patient safety. This study sought to determine the causes of early mortality (≤90 days) after AF ablation. We performed a retrospective analysis of AF ablation from January 1, 2013, to December 1, 2021 at the Mayo Clinic (Rochester, Phoenix, and Jacksonville). Causes of death were identified through a comprehensive chart review of the electronic health record from within the Mayo Clinic system and outside records when available. A total of 6723 patients were included in the study. The 90-day all-cause mortality rate was 0.22% (n=15). Among all 90-day deaths, majority of the deaths (73.3%) did not have a direct relationship with the procedure. Sudden death was the most common cause of early death (20%), followed by peri-procedural stroke (13%), respiratory failure (13%), atrioesophageal fistula (13%), infection (7%), heart failure (7%), and traumatic brain injury (7%). The 90-day mortality rate directly due to AF ablation procedural complications was 0.06% (n=4). AF ablation procedure has a 90-day mortality of 0.22%, and the most common cause of early mortality was sudden death. The majority (73.3%) of early mortality was not directly associated with a procedural complication, and the mortality rate due to complications associated with the AF ablation procedure was low at 0.06%. Further studies are required to investigate causes and risk factors associated with sudden death in this patient population.

Frequency of inter-specialty consensus decisions and adherence to advice following discussion at a weekly neurovascular multidisciplinary meeting

Background/aimsData are limited on the frequency of ‘consensus decisions’ between sub-specialists attending a neurovascular multidisciplinary meeting (MDM) regarding management of patients with extracranial carotid/vertebral stenoses and post-MDM ‘adherence’ to such advice.MethodsThis prospective audit/quality improvement project collated prospectively-recorded data from a weekly Neurovascular/Stroke Centre MDM documenting the proportion of extracranial carotid/vertebral stenosis patients in whom ‘consensus management decisions’ were reached by neurologists, vascular surgeons, stroke physicians-geriatricians and neuroradiologists. Adherence to MDM advice was analysed in asymptomatic carotid stenosis (ACS), symptomatic carotid stenosis (SCS), ‘indeterminate symptomatic status stenosis’ (ISS) and vertebral artery stenosis (VAS) patients, including intervals between index event to MDM + / − intervention.ResultsOne hundred fifteen patients were discussed: 108 with carotid stenosis and 7 with VAS. Consensus regarding management was noted in 96.5% (111/115): 100% with ACS and VAS, 96.2% with SCS and 92.9% with ISS. Adherence to MDM management advice was 96.4% (107/111): 100% in ACS, ISS and VAS patients; 92% (46/50) in SCS patients. The median interval from index symptoms to revascularisation in 50–99% SCS patients was 12.5 days (IQR: 9–18.3 days; N = 26), with a median interval from MDM to revascularisation of 5.5 days (IQR: 1–7 days). Thirty patients underwent revascularisation. Two out of twenty-nine patients (6.9%) with either SCS or ISS had a peri-procedural ipsilateral ischaemic stroke, with no further strokes/deaths during 3-months follow-up.ConclusionsThe high frequency of inter-specialty consensus regarding management and adherence to proposed treatment supports a collaborative/multidisciplinary model of care in patients with extracranial arterial stenoses. Service development should aim to shorten times between MDM discussion-intervention and optimise prevention of stroke/death.

313 Passive Flow-Reversal With Balloon-Guide Catheter for Transfemoral Carotid Artery Stenting: Proof of Concept, Technical Description and Experience

INTRODUCTION: The use of modern transfemoral balloon guide catheters (BGC) for flow reversal during carotid artery stenting (CAS) is scarcely described in literature but represents a promising and efficient technique for embolic protection. METHODS: We performed a retrospective analysis of patients ≥ 18-year-old who underwent elective CAS with the use of flow-reversal through the Walrus BGC. The BGC is positioned in the common carotid artery and inflated, followed by opening of the stop-cock for passive reversal of flow. We utilized a robotic transcranial Doppler monitoring during this technique for proof of concept. Patients’ characteristics, procedural details and clinical follow-up were evaluated. RESULTS: One-hundred and ten patients were included. Mean age was 69.1 years ± SD 9.6 and 30 (27.3%) were female. Most common comorbidities were hyperlipidemia (81.8%) and hypertension (73.6%). 54 (49.1%) patients were symptomatic. 102 (92.7%) patients had stenosis ≥70%. Contralateral stenosis ≥50% was present in 54 (49.1%) patients. Distal filters were used in 91 (82.7%) cases. Angioplasty was performed in 86 (78.2%) patients. Stenting was successful in 100% of cases. There were no periprocedural TIA or stroke. Stroke or TIA and mortality were both observed in only two (1.8%) patients during 30-days follow-up, of which one was due to non-compliance with antiplatelet regimen. CONCLUSIONS: In our institution’s experience, this technique was safe, feasible and efficient, with 100% technical success and no periprocedural thromboembolic complications. More extensive studies are needed to establish the role of proximal protection with flow-reversal using modern BGCs.

Resultados intrahospitalarios tras tratamiento percutáneo frente a quirúrgico en pacientes con estenosis aórtica y enfermedad arterial coronaria concomitante

Introduction and objectivesConcomitant coronary artery disease (CAD) is prevalent among aortic stenosis patients; however the optimal therapeutic strategy remains debated. We investigated periprocedural outcomes among patients undergoing transcatheter aortic valve implantation with percutaneous coronary intervention (TAVI/PCI) vs surgical aortic valve replacement with coronary artery bypass grafting (SAVR/CABG) for aortic stenosis with CAD. MethodsUsing discharge data from the Spanish National Health System, we identified 6194 patients (5217 SAVR/CABG and 977 TAVI/PCI) between 2016 and 2019. Propensity score matching was adjusted for baseline characteristics. The primary outcome was in-hospital all-cause mortality. Secondary outcomes were in-hospital complications and 30-day cardiovascular readmission. ResultsMatching resulted in 774 pairs. In-hospital all-cause mortality was more common in the SAVR/CABG group (3.4% vs 9.4%, P <.001) as was periprocedural stroke (0.9% vs 2.2%; P=.004), acute kidney injury (4.3% vs 16.0%, P <.001), blood transfusion (9.6% vs 21.1%, P <.001), and hospital-acquired pneumonia (0.1% vs 1.7%, P=.001). Permanent pacemaker implantation was higher for matched TAVI/PCI (12.0% vs 5.7%, P <.001). Lower volume centers (< 130 procedures/y) had higher in-hospital all-cause mortality for both procedures: TAVI/PCI (3.6% vs 2.9%, P <.001) and SAVR/CABG (8.3 vs 6.8%, P <.001). Thirty-day cardiovascular readmission did not differ between groups. ConclusionsIn this large contemporary nationwide study, percutaneous management of aortic stenosis and CAD with TAVI/PCI had lower in-hospital mortality and morbidity than surgical intervention. Higher volume centers had less in-hospital mortality in both groups. Dedicated national high-volume heart centers warrant further investigation.

Management of Coronary Artery Disease in CADASIL Patients: Review of Current Literature.

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common heritable form of vascular dementia in adults. It is well-established that CADASIL results in neurocognitive dysfunction and mood disturbance. There is also cumulative evidence that CADASIL patients are more susceptible to ischemic heart disease. The aim of this study is to review the current literature regarding the incidence of coronary artery disease in CADASIL patients with a focus on the various management options and the clinical challenges associated with each of these treatment strategies. We conducted a literature search using Cochrane, MEDLINE, and EMBASE for papers that reported the occurrence of coronary artery disease in patients with CADASIL. We supplemented the search with a manual search in Google Scholar. Only case reports, case series, and original articles were included. The search resulted in six reports indicating the association between coronary artery disease and CADASIL and its management. Evidence suggests that extracranial manifestations of CADASIL may include coronary artery disease, presenting as a more extensive burden of disease in younger patients. Surgical and percutaneous revascularization strategies are feasible, but the incidence of peri-procedural stroke remains significant and should be weighed against the potential benefit derived from either of these strategies. A multidisciplinary approach to therapy, with perspectives from neurologists, cardiologists, and cardiac surgeons, is needed to provide the appropriate treatment to the CADASIL patient with severe coronary artery disease. Future studies should be directed toward the development of targeted therapies that may help with the early detection and prevention of disease progress in these patients.

Stroke Prevention With Left Atrial Appendage Closure in Patients With Atrial Fibrillation and Prior Intracranial Hemorrhage

BackgroundOral anticoagulation (OAC) is deemed a relative contraindication after intracranial hemorrhage (ICH) if the cause cannot be eliminated and the risk of recurrence is high. That leaves atrial fibrillation (AF) patients at high risk of thromboembolic events. Endovascular left atrial appendage closure (LAAC) can be an alternative to OAC for patients requiring stroke prevention. MethodsWe performed a retrospective single-centre analysis of 138 consecutive ICH patients with nonvalvular AF and high stroke risk who underwent LAAC between 2010 and 2022 at Vancouver General Hospital. We report the baseline characteristics, procedural results, and follow-up data, comparing the observed stroke/transient ischemic attack (TIA) rate with the predicted event rate based on their CHA2DS2-VASc scores. ResultsThe average age was 76.1 ± 8.5 years; the mean CHA2DS2-VASc score was 4.4 ± 1.5; and the mean HAS-BLED score was 3.7 ± 0.9. The procedural success rate was 98.6%, and the complication rate was 3.6% with no periprocedural death, stroke, or TIA. The antithrombotic regimen post-LAAC consisted of short-term dual antiplatelet therapy (1-6 months) followed by aspirin alone for a minimum of 6 months in 86.2%. At mean follow-up of 14.7 ± 13.7 months, 9 deaths (6.5%, 7 cardiovascular, 2 noncardiovascular), 2 strokes (1.4%), and 1 TIA (0.7%) had occurred. The annualized observed stroke/TIA rate was 1.8%, which was lower than the adjusted predicted stroke rate of 7.0% (95% confidence interval: 4.8%-9.2%). Two patients (1.5%) suffered another ICH (both on aspirin monotherapy). One device-related thrombus (0.7%) was confirmed and treated with OAC without sequelae. ConclusionEndovascular LAAC is a feasible alternative to OAC for stroke prevention in patients with nonvalvular AF and prior ICH.

Outcomes and predictors of periprocedural stroke after transcatheter aortic valve implantation

BackgroundRisk factors for stroke after transcatheter aortic valve implantation (TAVI) are currently incompletely understood. PurposeTo identify possible predictors of early post-TAVI stroke and explore its short-term outcomes. MethodsRetrospective analysis of consecutive patients (pts) submitted to TAVI between 2009 and 2020 in a tertiary center. Baseline characteristics, procedural information and stroke in first 30 days after TAVI were collected. In-hospital and 12 months outcomes were analyzed. ResultsA total of 512pts (56,1% female, mean age of 82 ± 6years.) were included. In the first 30 days after TAVI 19pts (3,7%) had a stroke. In univariate analysis stroke was associated with higher body mass index (29 vs 27kg/m2, p=0.035), higher triglyceridemia (> 117,5mg/dL, p=0,002), lower high-density lipoprotein (< 38,5mg/dL, p=0,009) and porcelain aorta (36,8% vs 15,5%, p=0,014) and more frequent use of post-dilatation (58,8% vs 32%, p=0,021). In multivariate analysis, triglycerides > 117,5mg/dL (p=0,032, OR = 3,751) and post-dilatation (p=0,019, OR = 3,694) were the independent predictors. Stroke after TAVI was associated with longer intensive care unit stay (12 vs 4 days, p<0,001) and post-TAVI hospital stay (25 vs 10 days, p<0,0001), higher intra-hospital mortality (21,1% vs 4,3%, p=0,003), cardiovascular 30-day mortality (15,8% vs 4,1%, p=0,026) and 1-year stroke (13,2% vs 1,1%, p=0,003). ConclusionPeriprocedural and 30-day stroke is a relatively uncommon but potentially devastating complication after TAVI. In this cohort, 30-day stroke rate after TAVI was 3.7%. Hypertriglyceridemia and post-dilatation were found to be the only independent risk predictors. Outcomes after stroke, including 30-day mortality, were significantly worse.